# Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

> **NCT04034745** · — · WITHDRAWN · sponsor: **Andrew Hendifar, MD**

## Conditions studied

- Pancreatic Cancer
- Neuroendocrine Tumors
- Cachexia; Cancer

## Interventions

- **DRUG:** telotristat ethyl

## Key facts

- **NCT ID:** NCT04034745
- **Lead sponsor:** Andrew Hendifar, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2022-11
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2020-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034745, "Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04034745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*